2137673-43-7Relevant articles and documents
ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS
-
Paragraph 00163-00164, (2021/05/07)
Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, R6, X1, X2 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.
ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS
-
Paragraph 00137; 00164, (2021/05/07)
Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, X1, X2, X3 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.
